262 related articles for article (PubMed ID: 1402661)
1. Stable expression of transdominant Rev protein in human T cells inhibits human immunodeficiency virus replication.
Malim MH; Freimuth WW; Liu J; Boyle TJ; Lyerly HK; Cullen BR; Nabel GJ
J Exp Med; 1992 Oct; 176(4):1197-201. PubMed ID: 1402661
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of human immunodeficiency virus type 1 replication is enhanced by a combination of transdominant Tat and Rev proteins.
Ulich C; Harrich D; Estes P; Gaynor RB
J Virol; 1996 Jul; 70(7):4871-6. PubMed ID: 8676525
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by HIV-1-based lentivirus vectors expressing transdominant Rev.
Mautino MR; Keiser N; Morgan RA
J Virol; 2001 Apr; 75(8):3590-9. PubMed ID: 11264348
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of human immunodeficiency virus type 1 replication in human T cells by retroviral-mediated gene transfer of a dominant-negative Rev trans-activator.
Bevec D; Dobrovnik M; Hauber J; Böhnlein E
Proc Natl Acad Sci U S A; 1992 Oct; 89(20):9870-4. PubMed ID: 1409715
[TBL] [Abstract][Full Text] [Related]
5. Constitutive expression of chimeric neo-Rev response element transcripts suppresses HIV-1 replication in human CD4+ T lymphocytes.
Bevec D; Volc-Platzer B; Zimmermann K; Dobrovnik M; Hauber J; Veres G; Böhnlein E
Hum Gene Ther; 1994 Feb; 5(2):193-201. PubMed ID: 8186299
[TBL] [Abstract][Full Text] [Related]
6. Analysis of trans-dominant mutants of the HIV type 1 Rev protein for their ability to inhibit Rev function, HIV type 1 replication, and their use as anti-HIV gene therapeutics.
Ragheb JA; Bressler P; Daucher M; Chiang L; Chuah MK; VandenDriessche T; Morgan RA
AIDS Res Hum Retroviruses; 1995 Nov; 11(11):1343-53. PubMed ID: 8573391
[TBL] [Abstract][Full Text] [Related]
7. Expression of a protective gene-prolongs survival of T cells in human immunodeficiency virus-infected patients.
Woffendin C; Ranga U; Yang Z; Xu L; Nabel GJ
Proc Natl Acad Sci U S A; 1996 Apr; 93(7):2889-94. PubMed ID: 8610137
[TBL] [Abstract][Full Text] [Related]
8. Protection of primary human T cells from HIV infection by Trev: a transdominant fusion gene.
Chinen J; Aguilar-Cordova E; Ng-Tang D; Lewis DE; Belmont JW
Hum Gene Ther; 1997 May; 8(7):861-8. PubMed ID: 9143912
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of human immunodeficiency virus type 1 in human T cells by a potent Rev response element decoy consisting of the 13-nucleotide minimal Rev-binding domain.
Lee SW; Gallardo HF; Gilboa E; Smith C
J Virol; 1994 Dec; 68(12):8254-64. PubMed ID: 7966618
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of human immunodeficiency virus-1 (HIV-1) replication after transduction of granulocyte colony-stimulating factor-mobilized CD34+ cells from HIV-1-infected donors using retroviral vectors containing anti-HIV-1 genes.
Bauer G; Valdez P; Kearns K; Bahner I; Wen SF; Zaia JA; Kohn DB
Blood; 1997 Apr; 89(7):2259-67. PubMed ID: 9116267
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of HIV-1 replication by novel lentiviral vectors expressing transdominant Rev and HIV-1 env antisense.
Mautino MR; Morgan RA
Gene Ther; 2002 Apr; 9(7):421-31. PubMed ID: 11938457
[TBL] [Abstract][Full Text] [Related]
12. Genetic modification of human peripheral blood lymphocytes with a transdominant negative form of Rev: safety and toxicity.
Fox BA; Woffendin C; Yang ZY; San H; Ranga U; Gordon D; Osterholzer J; Nabel GJ
Hum Gene Ther; 1995 Aug; 6(8):997-1004. PubMed ID: 7578421
[TBL] [Abstract][Full Text] [Related]
13. Nonviral and viral delivery of a human immunodeficiency virus protective gene into primary human T cells.
Woffendin C; Yang ZY; Udaykumar ; Xu L; Yang NS; Sheehy MJ; Nabel GJ
Proc Natl Acad Sci U S A; 1994 Nov; 91(24):11581-5. PubMed ID: 7972106
[TBL] [Abstract][Full Text] [Related]
14. Transduction of human CD34+ hematopoietic progenitor cells by a retroviral vector expressing an RRE decoy inhibits human immunodeficiency virus type 1 replication in myelomonocytic cells produced in long-term culture.
Bahner I; Kearns K; Hao QL; Smogorzewska EM; Kohn DB
J Virol; 1996 Jul; 70(7):4352-60. PubMed ID: 8676458
[TBL] [Abstract][Full Text] [Related]
15. A combination anti-HIV-1 gene therapy approach using a single transcription unit that expresses antisense, decoy, and sense RNAs, and trans-dominant negative mutant Gag and Env proteins.
Ding SF; Lombardi R; Nazari R; Joshi S
Front Biosci; 2002 Feb; 7():a15-28. PubMed ID: 11815282
[TBL] [Abstract][Full Text] [Related]
16. Comparison of trans-dominant inhibitory mutant human immunodeficiency virus type 1 genes expressed by retroviral vectors in human T lymphocytes.
Bahner I; Zhou C; Yu XJ; Hao QL; Guatelli JC; Kohn DB
J Virol; 1993 Jun; 67(6):3199-207. PubMed ID: 8388497
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of human immunodeficiency virus type 1 by Tat/Rev-regulated expression of cytosine deaminase, interferon alpha2, or diphtheria toxin compared with inhibition by transdominant Rev.
Ragheb JA; Couture L; Mullen C; Ridgway A; Morgan RA
Hum Gene Ther; 1999 Jan; 10(1):103-12. PubMed ID: 10022535
[TBL] [Abstract][Full Text] [Related]
18. High transdominant RevM10 protein levels are required to inhibit HIV-1 replication in cell lines and primary T cells: implication for gene therapy of AIDS.
Plavec I; Agarwal M; Ho KE; Pineda M; Auten J; Baker J; Matsuzaki H; Escaich S; Bonyhadi M; Böhnlein E
Gene Ther; 1997 Feb; 4(2):128-39. PubMed ID: 9081703
[TBL] [Abstract][Full Text] [Related]
19. Regulated expression of a dominant negative form of Rev improves resistance to HIV replication in T cells.
Liu J; Woffendin C; Yang ZY; Nabel GJ
Gene Ther; 1994 Jan; 1(1):32-7. PubMed ID: 7584057
[TBL] [Abstract][Full Text] [Related]
20. Rev-free HIV-1 gene delivery system for targeting Rev-RRE-Crm1 nucleocytoplasmic RNA transport pathway.
Srinivasakumar N
PLoS One; 2011; 6(12):e28462. PubMed ID: 22164294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
